A splat on the wall. A tree stump with a doorknob. Flowers in a swamp that partially hid a school of flying piranhas. Rupert’s brain could not interpret the solid red canvas at all. He turned to his hostess and asked, “Is this your company’s, um, famous art collection? I’ve read so much about it.”
Sonia giggled and gazed down at Rupert from atop her 8 inch stiletto heels. “Oh, no, Mr. Madasheck, this is the annual employee’s children’s art exhibit.”
Rupert looked at a sculpture nestled on a pedestal and said, “That explains why this one looks like, um, well, like it was inspired by the family pet. Or its business.”
Sonia gasped in horror. “Oh, not that one! That is an original Brancusi from his early stage over a century ago.”
Rupert held his hands behind his back and glared at the pile on the pedestal. “Well,” he said. “Speaking of business, let’s get on with it. I’ve probably just destroyed any chance at a licensing agreement with you, haven’t I? Assuming I had a chance five minutes ago.”
As bridges and buildings crumble, is Biotech funding the arts?
There must be art lovers in the Biotech world. Rupert might not be one of them. Or is he?
Is it true that Cappuccino Pharmaceuticals is planning to donate $475 million to artists who will paint pictures of dogs playing cards while sipping cappuccinos?